Search Results: (30 results)

The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors. The study is enrolling people with BRCA1 or BRCA2 inherited mutations and have HER2-negative breast cancer, prostate cancer, pancreatic cancer, high grade ovarian, fallopian tube or primary peritoneal cancer; or other solid tumors with certain genetic mutations. 

This research study is enrolling prostate cancer patients who plan to undergo surgery to have their prostate removed (radical prostatectomy) and whose cancer has one of the listed gene mutations: BRCA1, BRCA2, PALB2, RAD51B, RAD51C, RAD51D, RAD54L2, BARD1, FANCA or BRIP1.

We are conducting a fully-online research study to learn more about how genes affect your risk of breast cancer. No office visit is required. Participants provide consent online, answer questions online about their health and medical history, and provide DNA via a saliva sample using a pre-paid mailer through the mail. In return for participation, study participants may receive information about their genetic ancestry for free.

PROMISE is a nationwide registry of prostate cancer patients with inherited mutations; screening approximately 5,000 participants with a prostate cancer diagnosis. The PROMISE team is studying how these mutations affect patient outcomes and hope to help patients learn more about their disease, the treatments that they may benefit most from, and any research studies that they may be eligible for.

This study is for people with advanced or metastatic breast cancer, have a BRCA1 or BRCA2 genetic mutation and were previously treated with a PARP inhibitor. The study will examine how effective  Olaparib in combination with Cediranib or Ceralasertib is in reducing the size of cancer and determining the length of time patients respond well to the treatment.

CAPS5 is a study looking at screening for early cancer in people with an elevated lifetime risk of developing pancreatic cancer. The goal is to study biomarkers derived from images and tissue samples (blood, pancreas fluid, duodenal fluid) for the early detection of pancreatic cancer and precancerous lesions.

This is a study to test the effectiveness of a drug (denosumab) on preventing the development of breast cancer in women with an inherited BRCA1 mutation.

Denosumab is a drug that is currently used to treat bone loss in order to reduce the risk of broken bones in healthy people, and is also used to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women with an inherited BRCA1 mutation.

This study is looking at the safety of, and the immune system response to a vaccine in people diagnosed with pancreatic cancer. The vaccine will  be administered after chemotherapy, but before surgery. The vaccine will incorporate proteins that can trigger an immune response and will be given along with a drug called poly-ICLC which can also activate immune cells.

This study will explore how well cognitive training helps breast cancer survivors with their memory and thinking problems caused by cancer.

SOROCk [NRG-CC008] is a clinical trial studying if removal of just the fallopian tubes can reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes among women with an inherited BRCA1 mutation. The main benefit of removing only the fallopian tubes and not the ovaries is to prevent surgically-induced menopause. The study will also examine various patient-reported quality of life outcomes. Researchers believe that most ovarian cancers first begin in the fallopian tubes, suggesting that removing the fallopian tubes only may prevent the development of ovarian cancer. This concept has never been formally testing in a clinical trial.

The PATROL (Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease) study is for people at risk for prostate cancer because they carry one or more genes that are known or suspected to increase prostate cancer risk: BRCA2, HOXB13, ATM, BRCA1, MLH1, MSH2, MSH6, PALB2, PMS2, CHEK2, RAD51D, or TP53.

This study will interview palliative care patients and/or their adult family members (spouse, parents, children, siblings) who have been offered and involved in genetic testing or counseling related to the condition for which the patients are receiving palliative care.

This study explores how different levels of support systems influence coping strategies among LGBTQIA+ cancer patients, specifically patients who are over the age of 18, actively diagnosed with cancer, and reside in the United States.

Researchers are conducting a survey of cancer patients who were diagnosed with breast, colorectal, gastric or prostate cancer within the past twenty years. The aim is to gather information about their diagnosis, treatment, and personal experiences of battling cancer. The survey will collect data on the type of cancer, diagnosis, treatment plan, medications used, and personal stories throughout the journey to help gain a better understanding of the emotional and psychological impact of cancer on patients.

This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).

The purpose of this study is to get participants’ opinions on the content, format, and design of educational materials that inform about the emotional consequences of undergoing a bilateral mastectomy.

This study will test whether endometrial samples from tampons can be used for early detection of endometrial cancer and is open to women over 45 years of age who are undergoing hysterectomy surgery (surgery to remove the uterus)

This study is being done to assess the safety and effectiveness of a series of vaccines (Tri-Ad5), together with another drug (N-803) that magnifies the body’s response to vaccines, to see if there is an effect on the risk of developing colon and other cancers in LS patients.

Survey for cancer caregivers of an LGBTQIA+ family member or friend to understand the impact of caregiving on the mental, physical, and financial well-being of LGBTQ+ people providing unpaid care

This study compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer.

The goal of this study is to measure whether a web-based patient-reported symptom monitoring and self management portal, Young, Empowered & Strong (YES), improves the quality of life of young breast cancer survivors when compared to standard of care symptom management. 

Researchers at Pfizer and Arvinas are conducting the TACTIVE-U studies for people with ER-positive, HER2-negative advanced or metastatic breast cancer who have received at least one prior round of treatment and no more than two prior rounds of treatments for advanced or metastatic disease. One of these rounds of treatment must have included a CDK4/6 inhibitor (e.g., Kisqali, Verzenio, Ibrance). The TACTIVE-U studies are looking at the safety of an oral study medicine, ARV-471 (also known as vepdegestrant), and how well it works when combined with other breast cancer medicines.

FORCE is conducting a short survey to better understand the unmet needs of people who are at high risk for colorectal, pancreatic or prostate cancer. You can take the survey here. 

The LiFT UP Study is a research project for individuals and families from around the world. The goal is to learn more about adults and children who have a change in the TP53 gene in their blood to better predict their specific cancer risks. 

Roadmap to Parenthood is a remote, survey-based study. Eligible participants must be aged 18-45, assigned female at birth, and history of a cancer diagnosis. this study to evaluate an online tool developed to educate and provide support to women and people assigned female at birth who are interested in family building after cancer. This study involves the completion of four online surveys. All study procedures are done remotely.

This research registry will collect and save data, cancer samples and family health history information to discover new ways cancer develops. It will look to find new genes that could be used for treatments and preventing cancer for people with hereditary cancer.

Study of a new drug called ONM-501 for people with triple negative breast cancer, advanced solid tumors or lymphomas

This study will examine the effectiveness and safety of cemiplimab, a treatment given prior to surgery. Participants will undergo endoscopy after the therapy and take CT scans to assess the effects of the therapy. The study also will compare genes of pretreatment cancer samples between patients who responded well to the therapy and patients who did not.

PreCharge is an IRB approved, nationwide study funded by the National Cancer Institute. The purpose of this study is to test a digital program designed to help people affected by hereditary cancer and who have not been diagnosed with cancer improve their mental and emotional well-being.

This study aims to interview those who tested positive for an adult-onset cancer predisposition as a minor to highlight their attitudes regarding predispositional genetic testing in childhood. Results may help guide clinicians in how they approach and navigate conversations about genetic testing in presymptomatic minors.